Plitidepsin: Physiology and What Research Reports

What Plitidepsin Is

Plitidepsin, also known as dehydrodidemnin B and developed under the name Aplidin, is a cyclic depsipeptide: a ring-shaped molecule built from amino acid units joined by both amide and ester bonds. That ester linkage is what separates a depsipeptide from a conventional peptide, and it contributes to the molecule's rigidity and metabolic stability. A review of its design and development described plitidepsin as a marine-derived compound advanced through oncology drug development programmes (PMID 28176904).

It is important to be clear about one point of physiology: plitidepsin is not an endogenous human peptide. It is not secreted by a gland, it has no measured baseline level in blood, and it plays no normal role in human metabolism. What makes it relevant to readers of physiology material is its target, which is a normal and abundant human protein.

Where It Comes From

Plitidepsin was originally isolated from the Mediterranean marine tunicate Aplidium albicans, a sessile filter-feeding invertebrate. Because harvesting sufficient material from marine sources is impractical, the compound used in research is produced by total chemical synthesis. Reviews of marine-derived agents have grouped plitidepsin with trabectedin as examples of ocean-sourced chemistry translated into clinical investigation, and reported that both compounds acted on components of the tumour microenvironment in addition to tumour cells themselves (PMID 24473171).

What It Does in the Body: the eEF1A Axis

The best-characterised molecular partner of plitidepsin is eukaryotic translation elongation factor 1A (eEF1A). eEF1A is one of the most abundant proteins in the cytoplasm; its housekeeping job is to deliver aminoacyl-tRNA to the ribosome during the elongation step of protein synthesis. Humans express two closely related isoforms, eEF1A1 and eEF1A2, with distinct tissue distributions.

Mechanistic findings

Mechanistic work summarised in the investigational-drug literature reported that plitidepsin bound eEF1A2 and that this interaction was followed by oxidative stress, sustained activation of the JNK stress-kinase pathway, and apoptosis in tumour cells (PMID 19513942). Rather than acting as a simple inhibitor of protein synthesis, the mechanism described in that literature involves converting an abundant housekeeping factor into a trigger for programmed cell death (PMID 19513942).

The same target is the reason plitidepsin appeared in virology. Reviews of its antiviral repurposing reported that SARS-CoV-2 depends on host eEF1A to translate its own proteins, and that blocking this host factor inhibited viral replication in laboratory systems (PMID 34357135). A 2025 review described this shift from oncology candidate to antiviral candidate as a pharmacological reprogramming of the molecule around its host target (PMID 41218566).

How Plitidepsin Is Measured and Studied

Because plitidepsin is exogenous, it is not "measured" as a physiological marker the way cortisol or IGF-1 might be. Instead, research measures its concentration and its effects:

• Pharmacokinetics. A population pharmacokinetic meta-analysis pooled plasma concentration data from cancer subjects who received plitidepsin by intravenous infusion and built a model of its disposition across studies (PMID 18941750). All of the clinical literature describes intravenous, hospital-administered use.
• Cell-based assays. Researchers assess cytotoxicity, apoptosis markers and stress-kinase activation in tumour cell lines, and viral yield or cytopathic effect in infected cell cultures (PMID 19513942).
• Target engagement. Studies characterise binding to eEF1A isoforms and the downstream signalling consequences (PMID 34357135).

What the Literature Reports

Oncology research

Reviews of plitidepsin in haematology reported that it was studied in relapsed or refractory multiple myeloma, evaluated in combination with dexamethasone (PMID 32406881). A separate review of the same indication discussed its development as a potential option in the relapsed/refractory setting and the rationale behind combination use (PMID 30111169). In solid tumours, a preclinical report described activity of plitidepsin against clear cell carcinoma of the ovary in laboratory models (PMID 34475047).

Antiviral research

A Spanish-language review grouped plitidepsin, an inhibitor of the elongation factor eEF1A, with molnupiravir, a ribonucleoside analogue, and reported intense activity of both compounds against SARS-CoV-2 in experimental systems (PMID 33902254). More recently, researchers characterised plitidepsin as an antiviral candidate against monkeypox virus infection, reporting activity in laboratory infection models (PMID 40675496). Reviews of this host-directed strategy noted that targeting a host factor rather than a viral protein is a conceptually different approach to resistance than direct-acting antivirals (PMID 41218566).

Plitidepsin Adverse Events: What Studies Report

The published record on plitidepsin tolerability comes from supervised intravenous administration in oncology trials, not from any other setting. A review of its design and development addressed tolerability explicitly as one of the factors shaping its potential place in therapy, alongside efficacy data (PMID 28176904). Reviews focused on multiple myeloma likewise framed the clinical picture in terms of both activity and the management of treatment-related events in a monitored hospital environment (PMID 30111169), and a further review of the myeloma indication summarised the clinical development programme in which those events were recorded (PMID 32406881). Readers looking for event-by-event frequencies should consult those primary trial publications directly, because summary reviews do not substitute for the original safety tables. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medicine, symptom or treatment decision.

Why It Matters to Peptide Readers

Plitidepsin is a useful teaching example for three reasons. First, it shows that the boundary between "peptide" and "small molecule drug" is blurry: a cyclic depsipeptide behaves pharmacologically more like a natural-product drug than like a signalling peptide. Second, it illustrates host-directed pharmacology — the target is a human protein, eEF1A, not a hormone receptor or a viral enzyme (PMID 34357135). Third, it demonstrates how a single mechanism can generate research programmes in completely different fields, from myeloma to poxvirus infection (PMID 40675496).

Limitations of the Current Evidence

Much of the antiviral literature is preclinical or review-level rather than definitive clinical evidence (PMID 41218566), and the ovarian carcinoma data cited above are explicitly described as preclinical (PMID 34475047). Pharmacokinetic modelling describes intravenous administration in cancer populations and cannot be extrapolated to other routes or populations (PMID 18941750). Plitidepsin is a cytotoxic investigational agent handled in clinical and laboratory settings; it is not a wellness or research-chemical category compound, and nothing on this page describes a protocol.

References

• Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor (Molecular Aspects of Medicine, 2025)
• Plitidepsin: design, development, and potential place in therapy (Drug Design, Development and Therapy, 2017)
• Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19 (Journal of Personalized Medicine, 2021)
• The mechanism of action of plitidepsin (Current Opinion in Investigational Drugs, 2009)
• Plitidepsin to treat multiple myeloma (Drugs of Today, 2020)
• Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir, an analogue of the ribonucleoside cytidine (Revista Española de Quimioterapia, 2021)
• Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma (Future Oncology, 2019)
• Preclinical Activity of Plitidepsin Against Clear Cell Carcinoma of the Ovary (Anticancer Research, 2021)
• Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects (Cancer Chemotherapy and Pharmacology, 2009)
• Functional characteristics of plitidepsin as an antiviral treatment against monkeypox virus infection (Antiviral Research, 2025)
• Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment (Marine Drugs, 2014)